medium chain triglyceride

Small moleculeapproved

Approved

Jul 13, 2016

A medium-chain triglyceride (MCT) is a triglyceride with two or three fatty acids having an aliphatic tail of 6–12 carbon atoms, i.e. a medium-chain fatty acid (MCFA). Rich food sources for commercial extraction of MCTs include palm kernel oil and coconut oil. — Wikipedia

Clinical trial activity

38 trials · 51 clinical orgs · 1 marketing orgs

Phase 1
5
Phase 2
6
Phase 3
3
Phase 4
4

Earliest trial started Nov 1, 2005 (NCT00336908)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jul 13, 2016

    Fresenius — Earliest FDA Approval

  3. Jul 13, 2016

    Fresenius — NDA Secondary Org

  4. Jul 13, 2016

    Fresenius — NDA Organization

Indications

Mechanism of action

  • Unspecified targetSupplementation

    supplementation

Combination products

Approval history

  • approvedJul 13, 2016

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • lipidem
  • medium chain triglyceride
  • medium chain triglycerides
  • medium chain triglycerides
  • medium-chain triglycerides
  • triglycerides, medium-chain

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07122531N/AAug 25, 2025University of Sherbrooke
NCT05705648N/AOct 1, 2023University of Alberta
NCT05937789N/AJul 1, 2023National Taiwan University
NCT05233917N/AJun 9, 2023Zhejiang University
NCT05357859N/AMay 3, 2022Taipei Medical University
NCT04780061Phase 3Jul 12, 2021New Roots Herbal, The Canadian College of Naturopathic Medicine, University of Ottawa, Vitazan Professional
NCT04905589N/AApr 30, 2021Nestle, University of Nottingham
NCT04584346Phase 1Jan 21, 2021National Institute of Neurological Disorders and Stroke (NINDS)
NCT04389983N/AMay 2, 2019University of Alberta
NCT03635879Phase 1Feb 13, 2019Cerecin
NCT03555019N/AApr 13, 2018Umea University, University of Geneva, University of Oslo
NCT03460444N/AMar 20, 2018University of British Columbia
NCT03282955Phase 4Jan 8, 2018B. Braun
NCT03117322Phase 4May 1, 2017Hospital Civil Juan I. Menchaca, University of Guadalajara
NCT03980327N/AJan 4, 2017University of British Columbia
NCT03610477N/AJan 1, 2017General Mills Inc., University of Minnesota
NCT02825745N/AJul 1, 2016University of London, Vitaflo
NCT02803177Phase 2Jun 1, 2016J. W. Goethe University
NCT02611102N/AMar 1, 2016United States Army
NCT02678390N/ASep 1, 2015University of Sherbrooke
Showing 20 of 38 trials
Page 1 / 2

Organizations

Research & Development (51)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of SherbrookeAcademic/Hospital4412013
University of AlbertaAcademic/Hospital3322005
B. BraunFor profit2222006
United States Department of AgricultureGovernment2012012
University of British ColumbiaAcademic/Hospital2212017
University of LondonAcademic/Hospital2122008
VitafloFor profit2122015
Centre de Salut Mental Infanto-Juvenil, LleidaAcademic/Hospital1012014
CerecinFor profit1112019
Children's National Medical CenterAcademic/Hospital1112014
Clever Instruments S.L.For profit1012014
Columbia UniversityAcademic/Hospital1112013
Complexa, Inc.For profit1112014
Fondation VitaeAcademic/Hospital1012015
General Mills Inc.For profit1012017
Hospital Civil Juan I. MenchacaAcademic/Hospital1112017
Jasper Clinic, Inc.For profit1012014
Johns Hopkins UniversityAcademic/Hospital1112015
Juvenile Diabetes Research FoundationAcademic/Hospital1012012
J. W. Goethe UniversityAcademic/Hospital1112016
51 organizations
Page 1 / 3

Marketing (2)

OrganizationOrg typeRelationshipDate
FreseniusFor profitNDA2Jul 13, 2016
FreseniusFor profitNDAJul 13, 2016